Glycerophospho-N-Oleoyl Ethanolamine
目录号 : GC14531
Precursor of oleoyl ethanolamide
Cas No.:201738-24-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Glycerophospho-N-Oleoyl Ethanolamine is the precursor of oleoyl ethanolamide (OEA). The fatty-acid ethanolamide, oleoylethanolamide (OEA) is a naturally occurring lipid. Oleoylethanolamide is an endogenous PPAR-α agonist. Oleoylethanolamide has been involved in modulating feeding and energy homeostasis by binding to peroxisome proliferator-activated receptor-alpha (PPAR-α) [1]. PPAR-α is a transcription factor and a major regulator of lipid metabolism in the liver. Activation of PPAR-α is mainly involved in fatty acid oxidation and expressed in liver, kidney, and skeletal muscle. Through ligand binding, PPAR-α promotes uptake, utilization, and catabolism of fatty acids [2].
OEA reduced food intake and lowered body-weight gain. Subchronic OEA treatment (5 mg/kg, i.p., once daily for two weeks) in Zucker rats initiated transcription of PPAR-α and other PPAR-α target gene [1]. OEA is an endogenous, potent agonist for PPARα. OEA activated PPARα with an EC50 value of 120 nM in a transactivation assay [3]. In rodents, intraperitoneal administration of OEA induced satiety and peripheral utilization of lipid substrate. Acute oral administration induced satiety [4].
References:
[1] Fu J, Oveisi F, Gaetani S, et al. Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats[J]. Neuropharmacology, 2005, 48(8): 1147-1153.
[2] Schiffrin E L, Amiri F, Benkirane K, et al. Peroxisome proliferator-activated receptors[J]. Hypertension, 2003, 42(4): 664-668.
[3] Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α[J]. Nature, 2003, 425(6953): 90-93.
[4] Thabuis C, Destaillats F, Tissot‐Favre D, et al. Oleoyl‐ethanolamide (OEA): A bioactive lipid derived from oleic acid and phosphatidylethanol‐amine[J]. Lipid Technology, 2007, 19(10): 225-227.
| Cas No. | 201738-24-1 | SDF | |
| 化学名 | mono(2,3-dihydroxypropyl)-mono[2-[[(9Z)-1-oxo-9-octadecenyl]amino]ethyl] ester phosphoric acid | ||
| Canonical SMILES | CCCCCCCC/C=C\CCCCCCCC(=O)NCCOP(=O)(O)OCC(O)CO | ||
| 分子式 | C23H46NO7P | 分子量 | 479.6 |
| 溶解度 | ≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0851 mL | 10.4254 mL | 20.8507 mL |
| 5 mM | 0.417 mL | 2.0851 mL | 4.1701 mL |
| 10 mM | 0.2085 mL | 1.0425 mL | 2.0851 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。